nodes	percent_of_prediction	percent_of_DWPC	metapath
Vardenafil—CYP3A4—Temozolomide—skin cancer	0.12	0.256	CbGbCtD
Vardenafil—CYP3A4—Imiquimod—skin cancer	0.12	0.256	CbGbCtD
Vardenafil—CYP3A4—Vismodegib—skin cancer	0.0835	0.177	CbGbCtD
Vardenafil—CYP3A4—Vemurafenib—skin cancer	0.066	0.14	CbGbCtD
Vardenafil—CYP3A5—Docetaxel—skin cancer	0.0581	0.123	CbGbCtD
Vardenafil—CYP3A4—Docetaxel—skin cancer	0.0227	0.0481	CbGbCtD
Vardenafil—PDE5A—penis—skin cancer	0.0196	0.221	CbGeAlD
Vardenafil—PDE11A—epithelium—skin cancer	0.00905	0.102	CbGeAlD
Vardenafil—PDE5A—endothelium—skin cancer	0.00767	0.0862	CbGeAlD
Vardenafil—PDE5A—blood vessel—skin cancer	0.00708	0.0795	CbGeAlD
Vardenafil—PDE6H—head—skin cancer	0.00562	0.0631	CbGeAlD
Vardenafil—PDE6G—head—skin cancer	0.00541	0.0608	CbGeAlD
Vardenafil—PDE1B—female reproductive system—skin cancer	0.00433	0.0487	CbGeAlD
Vardenafil—PDE6G—lymph node—skin cancer	0.00379	0.0426	CbGeAlD
Vardenafil—PDE10A—head—skin cancer	0.00365	0.041	CbGeAlD
Vardenafil—PDE5A—connective tissue—skin cancer	0.00363	0.0408	CbGeAlD
Vardenafil—PDE1B—head—skin cancer	0.00362	0.0407	CbGeAlD
Vardenafil—PDE5A—epithelium—skin cancer	0.00344	0.0387	CbGeAlD
Vardenafil—PDE5A—female reproductive system—skin cancer	0.00256	0.0288	CbGeAlD
Vardenafil—PDE10A—lymph node—skin cancer	0.00256	0.0287	CbGeAlD
Vardenafil—PDE1B—lymph node—skin cancer	0.00254	0.0285	CbGeAlD
Vardenafil—PDE5A—head—skin cancer	0.00214	0.024	CbGeAlD
Vardenafil—PDE5A—lymph node—skin cancer	0.0015	0.0168	CbGeAlD
Vardenafil—PDE11A—G alpha (s) signalling events—MC1R—skin cancer	0.00103	0.0482	CbGpPWpGaD
Vardenafil—Infestation NOS—Temozolomide—skin cancer	0.000948	0.00227	CcSEcCtD
Vardenafil—Infestation—Temozolomide—skin cancer	0.000948	0.00227	CcSEcCtD
Vardenafil—Flushing—Bleomycin—skin cancer	0.000937	0.00224	CcSEcCtD
Vardenafil—Pharyngitis—Dactinomycin—skin cancer	0.000934	0.00223	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000919	0.0022	CcSEcCtD
Vardenafil—PDE10A—G alpha (s) signalling events—MC1R—skin cancer	0.000918	0.043	CbGpPWpGaD
Vardenafil—Insomnia—Imiquimod—skin cancer	0.000913	0.00218	CcSEcCtD
Vardenafil—Paraesthesia—Imiquimod—skin cancer	0.000906	0.00217	CcSEcCtD
Vardenafil—Dyspnoea—Imiquimod—skin cancer	0.0009	0.00215	CcSEcCtD
Vardenafil—Somnolence—Imiquimod—skin cancer	0.000897	0.00214	CcSEcCtD
Vardenafil—Hepatobiliary disease—Temozolomide—skin cancer	0.000897	0.00214	CcSEcCtD
Vardenafil—Photosensitivity reaction—Fluorouracil—skin cancer	0.000894	0.00214	CcSEcCtD
Vardenafil—Sinusitis—Temozolomide—skin cancer	0.00089	0.00213	CcSEcCtD
Vardenafil—Dyspepsia—Imiquimod—skin cancer	0.000888	0.00212	CcSEcCtD
Vardenafil—Erythema—Bleomycin—skin cancer	0.000878	0.0021	CcSEcCtD
Vardenafil—Hot flush—Docetaxel—skin cancer	0.000875	0.00209	CcSEcCtD
Vardenafil—Infestation NOS—Fluorouracil—skin cancer	0.000874	0.00209	CcSEcCtD
Vardenafil—Infestation—Fluorouracil—skin cancer	0.000874	0.00209	CcSEcCtD
Vardenafil—Flushing—Dactinomycin—skin cancer	0.000873	0.00209	CcSEcCtD
Vardenafil—Hypersensitivity—Vemurafenib—skin cancer	0.000872	0.00208	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Imiquimod—skin cancer	0.000871	0.00208	CcSEcCtD
Vardenafil—Menopausal symptoms—Docetaxel—skin cancer	0.000867	0.00207	CcSEcCtD
Vardenafil—Visual disturbance—Docetaxel—skin cancer	0.000863	0.00206	CcSEcCtD
Vardenafil—Pain—Imiquimod—skin cancer	0.000863	0.00206	CcSEcCtD
Vardenafil—Acute coronary syndrome—Fluorouracil—skin cancer	0.000861	0.00206	CcSEcCtD
Vardenafil—Myocardial infarction—Fluorouracil—skin cancer	0.000856	0.00205	CcSEcCtD
Vardenafil—Haemoglobin—Temozolomide—skin cancer	0.000856	0.00204	CcSEcCtD
Vardenafil—Haemorrhage—Temozolomide—skin cancer	0.000851	0.00203	CcSEcCtD
Vardenafil—Conjunctivitis—Fluorouracil—skin cancer	0.000849	0.00203	CcSEcCtD
Vardenafil—Asthenia—Vemurafenib—skin cancer	0.000849	0.00203	CcSEcCtD
Vardenafil—Hypoaesthesia—Temozolomide—skin cancer	0.000847	0.00202	CcSEcCtD
Vardenafil—Pharyngitis—Temozolomide—skin cancer	0.000845	0.00202	CcSEcCtD
Vardenafil—Urinary tract disorder—Temozolomide—skin cancer	0.000841	0.00201	CcSEcCtD
Vardenafil—Pruritus—Vemurafenib—skin cancer	0.000837	0.002	CcSEcCtD
Vardenafil—Connective tissue disorder—Temozolomide—skin cancer	0.000836	0.002	CcSEcCtD
Vardenafil—Urethral disorder—Temozolomide—skin cancer	0.000834	0.00199	CcSEcCtD
Vardenafil—Feeling abnormal—Imiquimod—skin cancer	0.000832	0.00199	CcSEcCtD
Vardenafil—Gastrointestinal pain—Imiquimod—skin cancer	0.000825	0.00197	CcSEcCtD
Vardenafil—Epistaxis—Fluorouracil—skin cancer	0.000824	0.00197	CcSEcCtD
Vardenafil—Visual impairment—Temozolomide—skin cancer	0.00082	0.00196	CcSEcCtD
Vardenafil—Sinusitis—Fluorouracil—skin cancer	0.00082	0.00196	CcSEcCtD
Vardenafil—Erythema—Dactinomycin—skin cancer	0.000819	0.00196	CcSEcCtD
Vardenafil—Ill-defined disorder—Bleomycin—skin cancer	0.000815	0.00195	CcSEcCtD
Vardenafil—Diarrhoea—Vemurafenib—skin cancer	0.00081	0.00193	CcSEcCtD
Vardenafil—Abdominal pain—Imiquimod—skin cancer	0.000798	0.00191	CcSEcCtD
Vardenafil—CYP3A4—female reproductive system—skin cancer	0.000798	0.00896	CbGeAlD
Vardenafil—Eye disorder—Temozolomide—skin cancer	0.000796	0.0019	CcSEcCtD
Vardenafil—Tinnitus—Temozolomide—skin cancer	0.000794	0.0019	CcSEcCtD
Vardenafil—Malaise—Bleomycin—skin cancer	0.000792	0.00189	CcSEcCtD
Vardenafil—Flushing—Temozolomide—skin cancer	0.00079	0.00189	CcSEcCtD
Vardenafil—Cardiac disorder—Temozolomide—skin cancer	0.00079	0.00189	CcSEcCtD
Vardenafil—Haemoglobin—Fluorouracil—skin cancer	0.000788	0.00188	CcSEcCtD
Vardenafil—Rhinitis—Fluorouracil—skin cancer	0.000786	0.00188	CcSEcCtD
Vardenafil—Haemorrhage—Fluorouracil—skin cancer	0.000784	0.00187	CcSEcCtD
Vardenafil—Dizziness—Vemurafenib—skin cancer	0.000783	0.00187	CcSEcCtD
Vardenafil—Hypoaesthesia—Fluorouracil—skin cancer	0.00078	0.00186	CcSEcCtD
Vardenafil—Pharyngitis—Fluorouracil—skin cancer	0.000778	0.00186	CcSEcCtD
Vardenafil—Angiopathy—Temozolomide—skin cancer	0.000772	0.00185	CcSEcCtD
Vardenafil—Immune system disorder—Temozolomide—skin cancer	0.000769	0.00184	CcSEcCtD
Vardenafil—Mediastinal disorder—Temozolomide—skin cancer	0.000767	0.00183	CcSEcCtD
Vardenafil—Ill-defined disorder—Dactinomycin—skin cancer	0.00076	0.00182	CcSEcCtD
Vardenafil—Liver function test abnormal—Docetaxel—skin cancer	0.000755	0.00181	CcSEcCtD
Vardenafil—Vomiting—Vemurafenib—skin cancer	0.000752	0.0018	CcSEcCtD
Vardenafil—Myalgia—Bleomycin—skin cancer	0.000748	0.00179	CcSEcCtD
Vardenafil—Chest pain—Bleomycin—skin cancer	0.000748	0.00179	CcSEcCtD
Vardenafil—Abdominal pain upper—Docetaxel—skin cancer	0.000747	0.00179	CcSEcCtD
Vardenafil—Orthostatic hypotension—Docetaxel—skin cancer	0.000747	0.00179	CcSEcCtD
Vardenafil—Rash—Vemurafenib—skin cancer	0.000746	0.00178	CcSEcCtD
Vardenafil—Mental disorder—Temozolomide—skin cancer	0.000746	0.00178	CcSEcCtD
Vardenafil—Dermatitis—Vemurafenib—skin cancer	0.000745	0.00178	CcSEcCtD
Vardenafil—Hypersensitivity—Imiquimod—skin cancer	0.000744	0.00178	CcSEcCtD
Vardenafil—Headache—Vemurafenib—skin cancer	0.000741	0.00177	CcSEcCtD
Vardenafil—Erythema—Temozolomide—skin cancer	0.000741	0.00177	CcSEcCtD
Vardenafil—Breast disorder—Docetaxel—skin cancer	0.000739	0.00177	CcSEcCtD
Vardenafil—Discomfort—Bleomycin—skin cancer	0.000739	0.00177	CcSEcCtD
Vardenafil—Malaise—Dactinomycin—skin cancer	0.000739	0.00177	CcSEcCtD
Vardenafil—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000737	0.00176	CcSEcCtD
Vardenafil—Cramp muscle—Docetaxel—skin cancer	0.000737	0.00176	CcSEcCtD
Vardenafil—Asthenia—Imiquimod—skin cancer	0.000724	0.00173	CcSEcCtD
Vardenafil—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000722	0.00172	CcSEcCtD
Vardenafil—Anaphylactic shock—Bleomycin—skin cancer	0.000717	0.00171	CcSEcCtD
Vardenafil—Back pain—Temozolomide—skin cancer	0.000717	0.00171	CcSEcCtD
Vardenafil—Pruritus—Imiquimod—skin cancer	0.000714	0.00171	CcSEcCtD
Vardenafil—Infection—Bleomycin—skin cancer	0.000712	0.0017	CcSEcCtD
Vardenafil—Dysphagia—Docetaxel—skin cancer	0.000707	0.00169	CcSEcCtD
Vardenafil—Nausea—Vemurafenib—skin cancer	0.000703	0.00168	CcSEcCtD
Vardenafil—Vision blurred—Temozolomide—skin cancer	0.000698	0.00167	CcSEcCtD
Vardenafil—Myalgia—Dactinomycin—skin cancer	0.000698	0.00167	CcSEcCtD
Vardenafil—Diarrhoea—Imiquimod—skin cancer	0.00069	0.00165	CcSEcCtD
Vardenafil—Discomfort—Dactinomycin—skin cancer	0.000689	0.00165	CcSEcCtD
Vardenafil—Angina pectoris—Docetaxel—skin cancer	0.000689	0.00165	CcSEcCtD
Vardenafil—Ill-defined disorder—Temozolomide—skin cancer	0.000688	0.00164	CcSEcCtD
Vardenafil—Erythema—Fluorouracil—skin cancer	0.000683	0.00163	CcSEcCtD
Vardenafil—Angioedema—Temozolomide—skin cancer	0.000677	0.00162	CcSEcCtD
Vardenafil—PDE11A—G alpha (s) signalling events—PTGER4—skin cancer	0.000677	0.0317	CbGpPWpGaD
Vardenafil—Hypotension—Bleomycin—skin cancer	0.00067	0.0016	CcSEcCtD
Vardenafil—Malaise—Temozolomide—skin cancer	0.000668	0.0016	CcSEcCtD
Vardenafil—Dizziness—Imiquimod—skin cancer	0.000667	0.00159	CcSEcCtD
Vardenafil—Vertigo—Temozolomide—skin cancer	0.000666	0.00159	CcSEcCtD
Vardenafil—Infection—Dactinomycin—skin cancer	0.000664	0.00159	CcSEcCtD
Vardenafil—Palpitations—Temozolomide—skin cancer	0.000655	0.00156	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000653	0.00156	CcSEcCtD
Vardenafil—Paraesthesia—Bleomycin—skin cancer	0.000644	0.00154	CcSEcCtD
Vardenafil—Vision blurred—Fluorouracil—skin cancer	0.000643	0.00154	CcSEcCtD
Vardenafil—Convulsion—Temozolomide—skin cancer	0.000642	0.00153	CcSEcCtD
Vardenafil—Vomiting—Imiquimod—skin cancer	0.000642	0.00153	CcSEcCtD
Vardenafil—Dyspnoea—Bleomycin—skin cancer	0.000639	0.00153	CcSEcCtD
Vardenafil—Rash—Imiquimod—skin cancer	0.000636	0.00152	CcSEcCtD
Vardenafil—Dermatitis—Imiquimod—skin cancer	0.000636	0.00152	CcSEcCtD
Vardenafil—Headache—Imiquimod—skin cancer	0.000632	0.00151	CcSEcCtD
Vardenafil—Arthralgia—Temozolomide—skin cancer	0.000631	0.00151	CcSEcCtD
Vardenafil—Myalgia—Temozolomide—skin cancer	0.000631	0.00151	CcSEcCtD
Vardenafil—Infestation NOS—Docetaxel—skin cancer	0.000631	0.00151	CcSEcCtD
Vardenafil—Infestation—Docetaxel—skin cancer	0.000631	0.00151	CcSEcCtD
Vardenafil—Anxiety—Temozolomide—skin cancer	0.000629	0.0015	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000627	0.0015	CcSEcCtD
Vardenafil—Discomfort—Temozolomide—skin cancer	0.000623	0.00149	CcSEcCtD
Vardenafil—Acute coronary syndrome—Docetaxel—skin cancer	0.000622	0.00149	CcSEcCtD
Vardenafil—Myocardial infarction—Docetaxel—skin cancer	0.000618	0.00148	CcSEcCtD
Vardenafil—Dry mouth—Temozolomide—skin cancer	0.000617	0.00147	CcSEcCtD
Vardenafil—Pain—Bleomycin—skin cancer	0.000613	0.00147	CcSEcCtD
Vardenafil—Conjunctivitis—Docetaxel—skin cancer	0.000613	0.00146	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000609	0.00146	CcSEcCtD
Vardenafil—Anaphylactic shock—Temozolomide—skin cancer	0.000605	0.00145	CcSEcCtD
Vardenafil—PDE10A—G alpha (s) signalling events—PTGER4—skin cancer	0.000603	0.0283	CbGpPWpGaD
Vardenafil—Infection—Temozolomide—skin cancer	0.000601	0.00144	CcSEcCtD
Vardenafil—Nausea—Imiquimod—skin cancer	0.000599	0.00143	CcSEcCtD
Vardenafil—Hepatobiliary disease—Docetaxel—skin cancer	0.000596	0.00143	CcSEcCtD
Vardenafil—Epistaxis—Docetaxel—skin cancer	0.000595	0.00142	CcSEcCtD
Vardenafil—Nervous system disorder—Temozolomide—skin cancer	0.000593	0.00142	CcSEcCtD
Vardenafil—Convulsion—Fluorouracil—skin cancer	0.000592	0.00141	CcSEcCtD
Vardenafil—Feeling abnormal—Bleomycin—skin cancer	0.000591	0.00141	CcSEcCtD
Vardenafil—Skin disorder—Temozolomide—skin cancer	0.000587	0.0014	CcSEcCtD
Vardenafil—Hyperhidrosis—Temozolomide—skin cancer	0.000585	0.0014	CcSEcCtD
Vardenafil—Myalgia—Fluorouracil—skin cancer	0.000581	0.00139	CcSEcCtD
Vardenafil—Chest pain—Fluorouracil—skin cancer	0.000581	0.00139	CcSEcCtD
Vardenafil—Discomfort—Fluorouracil—skin cancer	0.000574	0.00137	CcSEcCtD
Vardenafil—Pain—Dactinomycin—skin cancer	0.000572	0.00137	CcSEcCtD
Vardenafil—Haemoglobin—Docetaxel—skin cancer	0.000569	0.00136	CcSEcCtD
Vardenafil—Rhinitis—Docetaxel—skin cancer	0.000568	0.00136	CcSEcCtD
Vardenafil—Haemorrhage—Docetaxel—skin cancer	0.000566	0.00135	CcSEcCtD
Vardenafil—Hypoaesthesia—Docetaxel—skin cancer	0.000563	0.00135	CcSEcCtD
Vardenafil—Pharyngitis—Docetaxel—skin cancer	0.000562	0.00134	CcSEcCtD
Vardenafil—Urinary tract disorder—Docetaxel—skin cancer	0.000559	0.00134	CcSEcCtD
Vardenafil—Anaphylactic shock—Fluorouracil—skin cancer	0.000557	0.00133	CcSEcCtD
Vardenafil—Connective tissue disorder—Docetaxel—skin cancer	0.000556	0.00133	CcSEcCtD
Vardenafil—Urethral disorder—Docetaxel—skin cancer	0.000555	0.00133	CcSEcCtD
Vardenafil—Infection—Fluorouracil—skin cancer	0.000554	0.00132	CcSEcCtD
Vardenafil—Feeling abnormal—Dactinomycin—skin cancer	0.000551	0.00132	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000551	0.00132	CcSEcCtD
Vardenafil—Insomnia—Temozolomide—skin cancer	0.000547	0.00131	CcSEcCtD
Vardenafil—Gastrointestinal pain—Dactinomycin—skin cancer	0.000547	0.00131	CcSEcCtD
Vardenafil—Nervous system disorder—Fluorouracil—skin cancer	0.000546	0.00131	CcSEcCtD
Vardenafil—Visual impairment—Docetaxel—skin cancer	0.000546	0.0013	CcSEcCtD
Vardenafil—Tachycardia—Fluorouracil—skin cancer	0.000544	0.0013	CcSEcCtD
Vardenafil—Paraesthesia—Temozolomide—skin cancer	0.000543	0.0013	CcSEcCtD
Vardenafil—Dyspnoea—Temozolomide—skin cancer	0.000539	0.00129	CcSEcCtD
Vardenafil—Somnolence—Temozolomide—skin cancer	0.000538	0.00128	CcSEcCtD
Vardenafil—Dyspepsia—Temozolomide—skin cancer	0.000532	0.00127	CcSEcCtD
Vardenafil—Eye disorder—Docetaxel—skin cancer	0.000529	0.00126	CcSEcCtD
Vardenafil—Abdominal pain—Dactinomycin—skin cancer	0.000529	0.00126	CcSEcCtD
Vardenafil—Hypersensitivity—Bleomycin—skin cancer	0.000528	0.00126	CcSEcCtD
Vardenafil—Cardiac disorder—Docetaxel—skin cancer	0.000525	0.00126	CcSEcCtD
Vardenafil—Flushing—Docetaxel—skin cancer	0.000525	0.00126	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Temozolomide—skin cancer	0.000522	0.00125	CcSEcCtD
Vardenafil—Hypotension—Fluorouracil—skin cancer	0.000521	0.00124	CcSEcCtD
Vardenafil—Pain—Temozolomide—skin cancer	0.000517	0.00124	CcSEcCtD
Vardenafil—Asthenia—Bleomycin—skin cancer	0.000514	0.00123	CcSEcCtD
Vardenafil—Angiopathy—Docetaxel—skin cancer	0.000514	0.00123	CcSEcCtD
Vardenafil—Immune system disorder—Docetaxel—skin cancer	0.000511	0.00122	CcSEcCtD
Vardenafil—Mediastinal disorder—Docetaxel—skin cancer	0.00051	0.00122	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000508	0.00121	CcSEcCtD
Vardenafil—Pruritus—Bleomycin—skin cancer	0.000507	0.00121	CcSEcCtD
Vardenafil—Insomnia—Fluorouracil—skin cancer	0.000504	0.0012	CcSEcCtD
Vardenafil—Paraesthesia—Fluorouracil—skin cancer	0.0005	0.0012	CcSEcCtD
Vardenafil—Feeling abnormal—Temozolomide—skin cancer	0.000498	0.00119	CcSEcCtD
Vardenafil—Dyspnoea—Fluorouracil—skin cancer	0.000497	0.00119	CcSEcCtD
Vardenafil—Mental disorder—Docetaxel—skin cancer	0.000496	0.00119	CcSEcCtD
Vardenafil—Somnolence—Fluorouracil—skin cancer	0.000495	0.00118	CcSEcCtD
Vardenafil—Gastrointestinal pain—Temozolomide—skin cancer	0.000495	0.00118	CcSEcCtD
Vardenafil—Erythema—Docetaxel—skin cancer	0.000493	0.00118	CcSEcCtD
Vardenafil—Hypersensitivity—Dactinomycin—skin cancer	0.000493	0.00118	CcSEcCtD
Vardenafil—Dyspepsia—Fluorouracil—skin cancer	0.00049	0.00117	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000481	0.00115	CcSEcCtD
Vardenafil—Asthenia—Dactinomycin—skin cancer	0.00048	0.00115	CcSEcCtD
Vardenafil—Abdominal pain—Temozolomide—skin cancer	0.000478	0.00114	CcSEcCtD
Vardenafil—Back pain—Docetaxel—skin cancer	0.000477	0.00114	CcSEcCtD
Vardenafil—Pain—Fluorouracil—skin cancer	0.000477	0.00114	CcSEcCtD
Vardenafil—Muscle spasms—Docetaxel—skin cancer	0.000474	0.00113	CcSEcCtD
Vardenafil—PDE1B—G alpha (s) signalling events—MC1R—skin cancer	0.000465	0.0218	CbGpPWpGaD
Vardenafil—Feeling abnormal—Fluorouracil—skin cancer	0.000459	0.0011	CcSEcCtD
Vardenafil—Diarrhoea—Dactinomycin—skin cancer	0.000457	0.00109	CcSEcCtD
Vardenafil—Vomiting—Bleomycin—skin cancer	0.000456	0.00109	CcSEcCtD
Vardenafil—Rash—Bleomycin—skin cancer	0.000452	0.00108	CcSEcCtD
Vardenafil—Dermatitis—Bleomycin—skin cancer	0.000452	0.00108	CcSEcCtD
Vardenafil—Hypersensitivity—Temozolomide—skin cancer	0.000446	0.00106	CcSEcCtD
Vardenafil—Syncope—Docetaxel—skin cancer	0.000442	0.00106	CcSEcCtD
Vardenafil—Palpitations—Docetaxel—skin cancer	0.000435	0.00104	CcSEcCtD
Vardenafil—Asthenia—Temozolomide—skin cancer	0.000434	0.00104	CcSEcCtD
Vardenafil—Loss of consciousness—Docetaxel—skin cancer	0.000433	0.00104	CcSEcCtD
Vardenafil—Pruritus—Temozolomide—skin cancer	0.000428	0.00102	CcSEcCtD
Vardenafil—Convulsion—Docetaxel—skin cancer	0.000427	0.00102	CcSEcCtD
Vardenafil—Nausea—Bleomycin—skin cancer	0.000426	0.00102	CcSEcCtD
Vardenafil—Vomiting—Dactinomycin—skin cancer	0.000425	0.00102	CcSEcCtD
Vardenafil—Rash—Dactinomycin—skin cancer	0.000422	0.00101	CcSEcCtD
Vardenafil—Arthralgia—Docetaxel—skin cancer	0.00042	0.001	CcSEcCtD
Vardenafil—Chest pain—Docetaxel—skin cancer	0.00042	0.001	CcSEcCtD
Vardenafil—Myalgia—Docetaxel—skin cancer	0.00042	0.001	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000417	0.000996	CcSEcCtD
Vardenafil—Diarrhoea—Temozolomide—skin cancer	0.000414	0.000989	CcSEcCtD
Vardenafil—Hypersensitivity—Fluorouracil—skin cancer	0.000411	0.000981	CcSEcCtD
Vardenafil—Dry mouth—Docetaxel—skin cancer	0.00041	0.000981	CcSEcCtD
Vardenafil—Anaphylactic shock—Docetaxel—skin cancer	0.000402	0.000961	CcSEcCtD
Vardenafil—Dizziness—Temozolomide—skin cancer	0.0004	0.000956	CcSEcCtD
Vardenafil—Infection—Docetaxel—skin cancer	0.0004	0.000955	CcSEcCtD
Vardenafil—Nausea—Dactinomycin—skin cancer	0.000397	0.000949	CcSEcCtD
Vardenafil—Shock—Docetaxel—skin cancer	0.000396	0.000946	CcSEcCtD
Vardenafil—Nervous system disorder—Docetaxel—skin cancer	0.000394	0.000943	CcSEcCtD
Vardenafil—Pruritus—Fluorouracil—skin cancer	0.000394	0.000942	CcSEcCtD
Vardenafil—Tachycardia—Docetaxel—skin cancer	0.000393	0.000938	CcSEcCtD
Vardenafil—Skin disorder—Docetaxel—skin cancer	0.000391	0.000934	CcSEcCtD
Vardenafil—Vomiting—Temozolomide—skin cancer	0.000385	0.000919	CcSEcCtD
Vardenafil—Rash—Temozolomide—skin cancer	0.000381	0.000911	CcSEcCtD
Vardenafil—Diarrhoea—Fluorouracil—skin cancer	0.000381	0.000911	CcSEcCtD
Vardenafil—Dermatitis—Temozolomide—skin cancer	0.000381	0.00091	CcSEcCtD
Vardenafil—Headache—Temozolomide—skin cancer	0.000379	0.000905	CcSEcCtD
Vardenafil—Hypotension—Docetaxel—skin cancer	0.000376	0.000898	CcSEcCtD
Vardenafil—Dizziness—Fluorouracil—skin cancer	0.000368	0.000881	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000366	0.000876	CcSEcCtD
Vardenafil—Insomnia—Docetaxel—skin cancer	0.000364	0.000869	CcSEcCtD
Vardenafil—Paraesthesia—Docetaxel—skin cancer	0.000361	0.000863	CcSEcCtD
Vardenafil—Nausea—Temozolomide—skin cancer	0.000359	0.000858	CcSEcCtD
Vardenafil—Dyspnoea—Docetaxel—skin cancer	0.000359	0.000857	CcSEcCtD
Vardenafil—Somnolence—Docetaxel—skin cancer	0.000358	0.000854	CcSEcCtD
Vardenafil—Vomiting—Fluorouracil—skin cancer	0.000354	0.000847	CcSEcCtD
Vardenafil—Dyspepsia—Docetaxel—skin cancer	0.000354	0.000846	CcSEcCtD
Vardenafil—Rash—Fluorouracil—skin cancer	0.000351	0.00084	CcSEcCtD
Vardenafil—Dermatitis—Fluorouracil—skin cancer	0.000351	0.000839	CcSEcCtD
Vardenafil—Headache—Fluorouracil—skin cancer	0.000349	0.000834	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Docetaxel—skin cancer	0.000347	0.00083	CcSEcCtD
Vardenafil—Pain—Docetaxel—skin cancer	0.000344	0.000822	CcSEcCtD
Vardenafil—Feeling abnormal—Docetaxel—skin cancer	0.000331	0.000792	CcSEcCtD
Vardenafil—Nausea—Fluorouracil—skin cancer	0.000331	0.000791	CcSEcCtD
Vardenafil—Gastrointestinal pain—Docetaxel—skin cancer	0.000329	0.000786	CcSEcCtD
Vardenafil—PDE11A—Signaling Pathways—RHOU—skin cancer	0.000321	0.015	CbGpPWpGaD
Vardenafil—Abdominal pain—Docetaxel—skin cancer	0.000318	0.00076	CcSEcCtD
Vardenafil—PDE1B—G alpha (s) signalling events—PTGER4—skin cancer	0.000306	0.0143	CbGpPWpGaD
Vardenafil—Hypersensitivity—Docetaxel—skin cancer	0.000296	0.000708	CcSEcCtD
Vardenafil—PDE6G—Signaling Pathways—RHOU—skin cancer	0.000294	0.0137	CbGpPWpGaD
Vardenafil—Asthenia—Docetaxel—skin cancer	0.000289	0.00069	CcSEcCtD
Vardenafil—PDE10A—Signaling Pathways—RHOU—skin cancer	0.000286	0.0134	CbGpPWpGaD
Vardenafil—Pruritus—Docetaxel—skin cancer	0.000285	0.00068	CcSEcCtD
Vardenafil—Diarrhoea—Docetaxel—skin cancer	0.000275	0.000658	CcSEcCtD
Vardenafil—PDE1B—Downstream signal transduction—RASA1—skin cancer	0.000267	0.0125	CbGpPWpGaD
Vardenafil—Dizziness—Docetaxel—skin cancer	0.000266	0.000636	CcSEcCtD
Vardenafil—PDE11A—Signaling by GPCR—PTCH2—skin cancer	0.000265	0.0124	CbGpPWpGaD
Vardenafil—Vomiting—Docetaxel—skin cancer	0.000256	0.000611	CcSEcCtD
Vardenafil—Rash—Docetaxel—skin cancer	0.000254	0.000606	CcSEcCtD
Vardenafil—Dermatitis—Docetaxel—skin cancer	0.000253	0.000605	CcSEcCtD
Vardenafil—Headache—Docetaxel—skin cancer	0.000252	0.000602	CcSEcCtD
Vardenafil—PDE1B—Signaling by PDGF—RASA1—skin cancer	0.000242	0.0113	CbGpPWpGaD
Vardenafil—Nausea—Docetaxel—skin cancer	0.000239	0.000571	CcSEcCtD
Vardenafil—PDE10A—Signaling by GPCR—PTCH2—skin cancer	0.000236	0.0111	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—FOXO4—skin cancer	0.000233	0.0109	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signal transduction—FOXO4—skin cancer	0.000219	0.0103	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—FOXO4—skin cancer	0.000218	0.0102	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—FOXO4—skin cancer	0.000217	0.0102	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—FOXO4—skin cancer	0.000216	0.0101	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—MC1R—skin cancer	0.000211	0.00989	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—FOXO4—skin cancer	0.000203	0.00952	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—FOXO4—skin cancer	0.000203	0.00952	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—FOXO4—skin cancer	0.000201	0.00943	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—FOXO4—skin cancer	0.0002	0.00935	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—FOXO4—skin cancer	0.000199	0.00931	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—MC1R—skin cancer	0.000192	0.00898	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—MC1R—skin cancer	0.000188	0.00882	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—FOXO4—skin cancer	0.00018	0.00843	CbGpPWpGaD
Vardenafil—PDE6G—Signaling by Wnt—TERT—skin cancer	0.000172	0.00808	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—MC1R—skin cancer	0.000171	0.00801	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PTCH2—skin cancer	0.000157	0.00734	CbGpPWpGaD
Vardenafil—PDE6G—Disease—CSPG4—skin cancer	0.000155	0.00727	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—TLR7—skin cancer	0.000153	0.00718	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—RHOU—skin cancer	0.000145	0.00679	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PTCH2—skin cancer	0.000143	0.00671	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PTCH2—skin cancer	0.00014	0.00654	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—PTGER4—skin cancer	0.000139	0.00651	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—FOXO4—skin cancer	0.000138	0.00648	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—SHH—skin cancer	0.000137	0.0064	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—PTCH1—skin cancer	0.00013	0.00607	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—SMO—skin cancer	0.00013	0.00607	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—PTGER4—skin cancer	0.000126	0.00591	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—PTGER4—skin cancer	0.000124	0.0058	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—SHH—skin cancer	0.000122	0.00571	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—PTCH2—skin cancer	0.00012	0.00561	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—GLI2—skin cancer	0.000119	0.00556	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—SMO—skin cancer	0.000115	0.00541	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—PTCH1—skin cancer	0.000115	0.00541	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—BRAF—skin cancer	0.000115	0.0054	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—MC1R—skin cancer	0.000113	0.00531	CbGpPWpGaD
Vardenafil—PDE1B—G Protein Signaling Pathways—NRAS—skin cancer	0.000113	0.00529	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—PTGER4—skin cancer	0.000112	0.00527	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—GLI1—skin cancer	0.000112	0.00523	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—GLI2—skin cancer	0.000109	0.00509	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—BRAF—skin cancer	0.000107	0.00503	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—SUFU—skin cancer	0.000106	0.00496	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—GLI2—skin cancer	0.000106	0.00496	CbGpPWpGaD
Vardenafil—PDE6G—Disease—ENO2—skin cancer	0.000105	0.00494	CbGpPWpGaD
Vardenafil—PDE6G—Disease—SHH—skin cancer	0.000105	0.00494	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MC1R—skin cancer	0.000104	0.00485	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—GLI1—skin cancer	0.000102	0.00478	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—MC1R—skin cancer	0.000101	0.00473	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—GLI1—skin cancer	9.95e-05	0.00466	CbGpPWpGaD
Vardenafil—PDE1B—G Protein Signaling Pathways—KRAS—skin cancer	9.73e-05	0.00456	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—SUFU—skin cancer	9.68e-05	0.00454	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—MC1R—skin cancer	9.54e-05	0.00447	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—BRAF—skin cancer	9.52e-05	0.00446	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—SUFU—skin cancer	9.44e-05	0.00442	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—TLR7—skin cancer	8.93e-05	0.00418	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—MC1R—skin cancer	8.67e-05	0.00406	CbGpPWpGaD
Vardenafil—PDE6G—Disease—FOXO4—skin cancer	8.6e-05	0.00403	CbGpPWpGaD
Vardenafil—PDE1B—G Protein Signaling Pathways—HRAS—skin cancer	8.27e-05	0.00387	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—SHH—skin cancer	8.07e-05	0.00378	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—RASA1—skin cancer	8.02e-05	0.00376	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—FOXO4—skin cancer	7.9e-05	0.0037	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—NRAS—skin cancer	7.75e-05	0.00363	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CSPG4—skin cancer	7.66e-05	0.00359	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—SMO—skin cancer	7.65e-05	0.00359	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PTCH1—skin cancer	7.65e-05	0.00359	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PTGER4—skin cancer	7.45e-05	0.00349	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—SHH—skin cancer	7.38e-05	0.00346	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—RASA1—skin cancer	7.34e-05	0.00344	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—BRAF—skin cancer	7.32e-05	0.00343	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signal transduction—NRAS—skin cancer	7.29e-05	0.00341	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—NRAS—skin cancer	7.25e-05	0.0034	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—NRAS—skin cancer	7.22e-05	0.00338	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—SHH—skin cancer	7.2e-05	0.00337	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—NRAS—skin cancer	7.18e-05	0.00336	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—RASA1—skin cancer	7.15e-05	0.00335	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PTCH2—skin cancer	7.08e-05	0.00332	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PTCH1—skin cancer	7e-05	0.00328	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—SMO—skin cancer	7e-05	0.00328	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PTCH1—skin cancer	6.82e-05	0.0032	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—SMO—skin cancer	6.82e-05	0.0032	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PTGER4—skin cancer	6.82e-05	0.00319	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—NRAS—skin cancer	6.76e-05	0.00316	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—NRAS—skin cancer	6.76e-05	0.00316	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—NRAS—skin cancer	6.69e-05	0.00314	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—KRAS—skin cancer	6.67e-05	0.00313	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PTGER4—skin cancer	6.64e-05	0.00311	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—NRAS—skin cancer	6.64e-05	0.00311	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—NRAS—skin cancer	6.61e-05	0.00309	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—FOXO4—skin cancer	6.58e-05	0.00308	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—NRAS—skin cancer	6.45e-05	0.00302	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—PTGER4—skin cancer	6.27e-05	0.00294	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signal transduction—KRAS—skin cancer	6.27e-05	0.00294	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—KRAS—skin cancer	6.24e-05	0.00292	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—KRAS—skin cancer	6.21e-05	0.00291	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—KRAS—skin cancer	6.18e-05	0.00289	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—SHH—skin cancer	6.17e-05	0.00289	CbGpPWpGaD
Vardenafil—PDE6G—Disease—ERCC2—skin cancer	6.13e-05	0.00287	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—FOXO4—skin cancer	6.02e-05	0.00282	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	5.98e-05	0.0028	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—FOXO4—skin cancer	5.87e-05	0.00275	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—SMO—skin cancer	5.85e-05	0.00274	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—PTCH1—skin cancer	5.85e-05	0.00274	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—KRAS—skin cancer	5.81e-05	0.00272	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—KRAS—skin cancer	5.81e-05	0.00272	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—KRAS—skin cancer	5.76e-05	0.0027	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—NRAS—skin cancer	5.75e-05	0.00269	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—NRAS—skin cancer	5.75e-05	0.00269	CbGpPWpGaD
Vardenafil—PDE6G—Disease—TERT—skin cancer	5.74e-05	0.00269	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—KRAS—skin cancer	5.71e-05	0.00267	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—PTGER4—skin cancer	5.7e-05	0.00267	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—KRAS—skin cancer	5.69e-05	0.00266	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—HRAS—skin cancer	5.67e-05	0.00266	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—KRAS—skin cancer	5.55e-05	0.0026	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—IL6—skin cancer	5.43e-05	0.00254	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—GLI2—skin cancer	5.37e-05	0.00251	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signal transduction—HRAS—skin cancer	5.33e-05	0.0025	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—HRAS—skin cancer	5.3e-05	0.00248	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—HRAS—skin cancer	5.28e-05	0.00247	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—HRAS—skin cancer	5.25e-05	0.00246	CbGpPWpGaD
Vardenafil—PDE1B—Disease—SHH—skin cancer	5.21e-05	0.00244	CbGpPWpGaD
Vardenafil—PDE1B—Disease—ENO2—skin cancer	5.21e-05	0.00244	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	5.15e-05	0.00241	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MC1R—skin cancer	5.12e-05	0.0024	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signal transduction—IL6—skin cancer	5.1e-05	0.00239	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—IL6—skin cancer	5.08e-05	0.00238	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—IL6—skin cancer	5.05e-05	0.00237	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—GLI1—skin cancer	5.04e-05	0.00236	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—IL6—skin cancer	5.03e-05	0.00235	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—KRAS—skin cancer	4.95e-05	0.00232	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—KRAS—skin cancer	4.95e-05	0.00232	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—HRAS—skin cancer	4.94e-05	0.00231	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—HRAS—skin cancer	4.94e-05	0.00231	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—TP53—skin cancer	4.94e-05	0.00231	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—HRAS—skin cancer	4.9e-05	0.00229	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—HRAS—skin cancer	4.85e-05	0.00227	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—HRAS—skin cancer	4.83e-05	0.00226	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—SUFU—skin cancer	4.78e-05	0.00224	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—IL6—skin cancer	4.73e-05	0.00222	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—IL6—skin cancer	4.73e-05	0.00222	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—HRAS—skin cancer	4.72e-05	0.00221	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—IL6—skin cancer	4.69e-05	0.0022	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—IL6—skin cancer	4.65e-05	0.00218	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—IL6—skin cancer	4.63e-05	0.00217	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—NRAS—skin cancer	4.6e-05	0.00216	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—FOXO4—skin cancer	4.6e-05	0.00215	CbGpPWpGaD
Vardenafil—PDE6G—Disease—BRAF—skin cancer	4.55e-05	0.00213	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—TP53—skin cancer	4.4e-05	0.00206	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—TP53—skin cancer	4.4e-05	0.00206	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—TERT—skin cancer	4.4e-05	0.00206	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	4.38e-05	0.00205	CbGpPWpGaD
Vardenafil—PDE1B—Disease—FOXO4—skin cancer	4.25e-05	0.00199	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—HRAS—skin cancer	4.21e-05	0.00197	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—HRAS—skin cancer	4.21e-05	0.00197	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	4.19e-05	0.00196	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—TERT—skin cancer	4.02e-05	0.00188	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—KRAS—skin cancer	3.96e-05	0.00186	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—TERT—skin cancer	3.92e-05	0.00184	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—NRAS—skin cancer	3.7e-05	0.00173	CbGpPWpGaD
Vardenafil—PDE6G—Disease—PTGS2—skin cancer	3.67e-05	0.00172	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—SHH—skin cancer	3.65e-05	0.00171	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—RASA1—skin cancer	3.62e-05	0.0017	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—BRAF—skin cancer	3.48e-05	0.00163	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PTCH1—skin cancer	3.46e-05	0.00162	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—SMO—skin cancer	3.46e-05	0.00162	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—HRAS—skin cancer	3.37e-05	0.00158	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PTGER4—skin cancer	3.37e-05	0.00158	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—NRAS—skin cancer	3.3e-05	0.00155	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—IL6—skin cancer	3.22e-05	0.00151	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—KRAS—skin cancer	3.19e-05	0.00149	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—BRAF—skin cancer	3.18e-05	0.00149	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PLIN2—skin cancer	3.17e-05	0.00148	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—BRAF—skin cancer	3.1e-05	0.00145	CbGpPWpGaD
Vardenafil—PDE1B—Disease—ERCC2—skin cancer	3.03e-05	0.00142	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—FOXO4—skin cancer	2.97e-05	0.00139	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—NRAS—skin cancer	2.92e-05	0.00137	CbGpPWpGaD
Vardenafil—PDE6G—Disease—NRAS—skin cancer	2.86e-05	0.00134	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—KRAS—skin cancer	2.84e-05	0.00133	CbGpPWpGaD
Vardenafil—PDE1B—Disease—TERT—skin cancer	2.84e-05	0.00133	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—HRAS—skin cancer	2.71e-05	0.00127	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—NRAS—skin cancer	2.62e-05	0.00123	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—IL6—skin cancer	2.59e-05	0.00121	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—CSPG4—skin cancer	2.56e-05	0.0012	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—KRAS—skin cancer	2.51e-05	0.00118	CbGpPWpGaD
Vardenafil—PDE6G—Disease—KRAS—skin cancer	2.46e-05	0.00115	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—HRAS—skin cancer	2.42e-05	0.00113	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—IL6—skin cancer	2.31e-05	0.00108	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—KRAS—skin cancer	2.26e-05	0.00106	CbGpPWpGaD
Vardenafil—PDE1B—Disease—BRAF—skin cancer	2.25e-05	0.00105	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—TP53—skin cancer	2.23e-05	0.00104	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—NRAS—skin cancer	2.19e-05	0.00102	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—HRAS—skin cancer	2.13e-05	0.000999	CbGpPWpGaD
Vardenafil—PDE6G—Disease—HRAS—skin cancer	2.09e-05	0.000979	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—NRAS—skin cancer	2e-05	0.000937	CbGpPWpGaD
Vardenafil—PDE6G—Disease—IL6—skin cancer	2e-05	0.000937	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TERT—skin cancer	1.99e-05	0.00093	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—NRAS—skin cancer	1.95e-05	0.000913	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—HRAS—skin cancer	1.92e-05	0.000899	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—KRAS—skin cancer	1.88e-05	0.000882	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—IL6—skin cancer	1.84e-05	0.000861	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PTGS2—skin cancer	1.81e-05	0.00085	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—ENO2—skin cancer	1.74e-05	0.000814	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—KRAS—skin cancer	1.72e-05	0.000807	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—KRAS—skin cancer	1.68e-05	0.000786	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—TP53—skin cancer	1.67e-05	0.000784	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—NRAS—skin cancer	1.67e-05	0.000784	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—HRAS—skin cancer	1.6e-05	0.00075	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—BRAF—skin cancer	1.57e-05	0.000737	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—IL6—skin cancer	1.53e-05	0.000718	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—TP53—skin cancer	1.53e-05	0.000717	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—NRAS—skin cancer	1.53e-05	0.000716	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—TP53—skin cancer	1.49e-05	0.000699	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PLIN2—skin cancer	1.47e-05	0.00069	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—HRAS—skin cancer	1.46e-05	0.000686	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—KRAS—skin cancer	1.44e-05	0.000674	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—HRAS—skin cancer	1.43e-05	0.000668	CbGpPWpGaD
Vardenafil—PDE1B—Disease—NRAS—skin cancer	1.41e-05	0.000661	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—IL6—skin cancer	1.4e-05	0.000656	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—IL6—skin cancer	1.37e-05	0.00064	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—KRAS—skin cancer	1.32e-05	0.000616	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—HRAS—skin cancer	1.22e-05	0.000573	CbGpPWpGaD
Vardenafil—PDE1B—Disease—KRAS—skin cancer	1.21e-05	0.000569	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—CSPG4—skin cancer	1.19e-05	0.000556	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—IL6—skin cancer	1.17e-05	0.000549	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—HRAS—skin cancer	1.12e-05	0.000524	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—IL6—skin cancer	1.07e-05	0.000501	CbGpPWpGaD
Vardenafil—PDE1B—Disease—HRAS—skin cancer	1.03e-05	0.000484	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—ERCC2—skin cancer	1.01e-05	0.000473	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—NRAS—skin cancer	9.88e-06	0.000463	CbGpPWpGaD
Vardenafil—PDE1B—Disease—IL6—skin cancer	9.88e-06	0.000463	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—KRAS—skin cancer	8.51e-06	0.000398	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—ENO2—skin cancer	8.08e-06	0.000378	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TP53—skin cancer	7.56e-06	0.000354	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—HRAS—skin cancer	7.23e-06	0.000339	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—IL6—skin cancer	6.92e-06	0.000324	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PTGS2—skin cancer	6.05e-06	0.000283	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—ERCC2—skin cancer	4.69e-06	0.00022	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PTGS2—skin cancer	2.81e-06	0.000132	CbGpPWpGaD
